Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Researchers observe how lung cancer patients fare in real life

NCT ID NCT07173946

Knowledge-focused Sponsor: Peking Union Medical College Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study will follow 96 adults with extensive-stage small cell lung cancer to see how they are treated in everyday hospital settings and how they respond. Doctors will choose treatments as usual, and researchers will collect data from medical records and regular check-ins every 3 months. The goal is to learn what works best in real-world practice to improve future care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could provide valuable insights into how current treatments work in everyday practice, helping doctors refine strategies for ES-SCLC.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly test new therapies. Results may be limited by the small number of participants (96) and real-world variability.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 96 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2025

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients (age ≥18 years) with histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC), defined as stage IV according to the AJCC 9th edition cancer staging system, who are scheduled to receive any antitumor therapy (including chemotherapy, immunotherapy, etc.). Participants must provide informed consent and be willing to comply with treatment and follow-up procedures.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Aged 18 years or above 2. Histologically or cytologically confirmed diagnosis of small cell lung cancer, classified as extensive stage (AJCC 9th Edition Stage IV). 3. Signed informed consent, good compliance, and willingness to undergo treatment and follow-up. 4. Intended to receive any anticancer treatment, including chemotherapy or immunotherapy. Exclusion Criteria: 1. Lack of definitive histological diagnosis 2. Patients with limited-stage small cell lung cancer 3. Expected survival \< 3 months 4. Inability to undergo regular follow-up.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Extensive-stage small-cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Extensive-stage small-cell lung cancer Small cell lung cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.